Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California. Show more

Location: 1599 Industrial Road, San Carlos, CA, 94070, United States | Website: https://biomeafusion.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

102.6M

52 Wk Range

$1.29 - $13.07

Previous Close

$1.80

Open

$1.80

Volume

2,197,124

Day Range

$1.63 - $1.80

Enterprise Value

39.69M

Cash

35.86M

Avg Qtr Burn

-28.38M

Insider Ownership

9.76%

Institutional Own.

45.04%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
BMF-219 (icovamenib) Details
Type 1 diabetes

Big Mover™

Susp. Mover™

Phase 2

Data readout

Phase 2

Initiation

Phase 1/2

Data readout

Phase 1

Update

BMF-219 (icovamenib) Details
Acute myeloid leukemia, Acute lymphoblastic leukemia

Failed

Discontinued

BMF-219 (icovamenib) Details
Solid tumor/s, Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma

Failed

Discontinued